Findings
========

Multiple clinical trials have proven the efficacy of tissue plasminogen activator (tPA) in the treatment of acute focal cerebral ischemia \[[@B1]\]. Apart from its beneficial recanalizing actions, tPA has also detrimental effects contributing to blood-brain barrier (BBB) disruption in ischemia-affected brain tissue \[[@B2]-[@B4]\] with an increased risk of secondary hemorrhage and poor outcome \[[@B5],[@B6]\]. Enzymes, e.g., matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), are considered as key factors regulating the BBB integrity \[[@B7],[@B8]\]. Thereby, MMPs possess both destructive abilities in earlier phases of ischemia and regenerative properties (e.g., remodeling) in later phases \[[@B9]\], which implicate complex interactions in the time course of ischemic stroke. Interestingly, tPA was found to directly increase MMP levels in experimental and clinical stroke \[[@B4],[@B10]-[@B12]\], which is considered as a main tPA-related mechanism of BBB breakdown \[[@B3],[@B4],[@B13]\]. This led to increasing efforts to develop neuroprotective strategies with the aim to selectively attenuate tPA side effects \[[@B14]\]. In this regard, treatment with hyperoxia - the application of 100% oxygen under normal (normobaric oxygen; NBO) or elevated ambient pressure (hyperbaric oxygen; HBO) \[[@B15]\] - was discussed as potential co-treatment \[[@B16]\]. This rationale based on the reported positive effects of hyperoxia in experimental stroke, e.g., reduced degradation of BBB components, inhibition of MMP-9 upregulation \[[@B17]\], and decreased secondary hemorrhage when tPA was given following hyperoxia \[[@B18],[@B19]\]. Our group has recently demonstrated that hyperoxia, tPA and especially their simultaneous application differentially affects BBB permeability and alters plasma concentrations of MMPs and TIMPs \[[@B20]\].

Considering the potential clinical use of hyperoxia in acute ischemic stroke - especially in combination with tPA - we aimed to further clarify mechanisms of ischemia-related BBB alterations including the role of involved MMPs and TIMPs. Here, we tested the hypothesis that tPA and hyperoxia (i.e. NBO or HBO) influence the interrelations between BBB permeability, MMP-2/-9 and TIMP-1/-2 in the early phase of experimental focal cerebral ischemia.

For this purpose, we retrospectively analyzed data from our previous work \[[@B20]\]. The underlying study and the associated experimental animals procedures were approved by local authorities and conducted according to the 86/609/EEC. In detail, male Wistar rats underwent focal cerebral ischemia by right-sided embolic middle cerebral artery occlusion (eMCAO) as described previously \[[@B20],[@B21]\]. Two hours after eMCAO, the animals were treated with 60 minutes of NBO or HBO (2.4 absolute atmospheres) in a special oxygen chamber (Sayers/Hebold, Cuxhaven, Germany), tPA (Actilyse, Boehringer, Ingelheim, Germany; 9 mg/kg body weight intravenously over 30 minutes), combined tPA and HBO (tPA+HBO), or received no treatment (control). Four or 24 hours after ischemia onset *via*eMCAO, 20 mg of FITC-albumin (Sigma, Taufkirchen, Germany; in 1 mL physiological saline solution \[NaCl\]) was administered intravenously. After an additional circulation period of usually 1 hour, the animals were deeply anesthetized and blood samples for MMP-2, -9, TIMP-1 and -2 serum concentrations were obtained transcardially, followed by perfusion with NaCl and 4% paraformaldehyde in phosphate-buffered saline. Tissue preparation and quantification of BBB integrity in ischemia-affected brain regions using FITC-albumin as permeability marker were described previously \[[@B20],[@B22]\]. The resulting extra-/intravasal ratio was utilized for calculations in the present study. Overall, data from 78 animals were used for statistical analyses of interrelations between the extra-/intravasal FITC-albumin ratio as surrogate for ischemia-related BBB permeability, and serum concentrations of MMPs and TIMPs *via*time point-corrected (survival period) partial correlations. Calculations were made with SPSS 18.0 (SPSS Inc., an IBM Company, Chicago, IL); a *P*\< 0.05 was considered statistically significant.

We first focused on interrelations between the ischemia-induced changes in BBB permeability, MMP-2 and -9 in controls (Figure [1](#F1){ref-type="fig"}) to explore the natural pathophysiology in the applied model of experimental stroke. Non-significant but positive partial correlation coefficients were observed for both MMPs investigated, particularly MMP-2 (r = 0.317), indicating an unidirectional association between BBB permeability and plasma MMP concentrations. Figure [1](#F1){ref-type="fig"} further displays the results after treatment with hyperoxia (NBO or HBO), tPA and its combination with HBO. While we observed in NBO-treated animals negative correlation coefficients for both MMP-2 and -9, HBO resulted in a significant negative correlation (r = 0.606; *P*= 0.022) for MMP-9, representing an inverse association between BBB permeability and MMP levels. As expected, treatment with tPA led to unidirectional associations of BBB permeability and MMP levels as indicated by positive correlation coefficients, again pronouncing MMP-9. Interestingly, treatment with tPA+HBO resulted in inverse associations between BBB permeability and both MMPs when compared to tPA alone, but this effect was much lower as in groups treated with NBO or HBO alone. Second, we focused on interrelations between MMPs and TIMPs in all animal groups exploring the natural relationship of these enzymes in untreated focal cerebral ischemia (Table [1](#T1){ref-type="table"}), and after different treatments (Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). In controls, non-significant correlation coefficients were found, although values ranged from -0.314 (MMP-9 and TIMP-2) to 0.345 (MMP-2 and TIMP-2). A comparable situation was noted in NBO-treated animals (Table [2](#T2){ref-type="table"}, upper right), but interestingly, HBO led to interrelations with significant coefficients (Table [2](#T2){ref-type="table"}, lower left). Thereby, almost identical positive correlation coefficients of about 0.7 were obtained between TIMP-1 and MMP-9, TIMP-2 and MMP-9 as well as TIMP-1 and -2, clearly indicating treatment-specific alterations when compared to controls (Table [1](#T1){ref-type="table"}). For tPA (Table [3](#T3){ref-type="table"}, upper right), significant coefficients of about 0.7 were detected between TIMP-2 and MMP-9 as well as TIMP-1 and -2. In contrast, administration of tPA+HBO (Table [2](#T2){ref-type="table"}, lower left) did not affect the MMP-9 route significantly, but provided significant and positively directed correlation coefficients (about 0.6 and 0.8) between MMP-2 and TIMP-1 as well as TIMP-2. Notably, TIMP-1 and -2 were also significantly positively correlated after combined treatment with tPA and HBO, which has already been noted for tPA and HBO alone with nearly the same coefficients (about 0.76).

![**Time point-corrected partial correlation coefficients between the extra-/intravasal FITC-albumin ratio as surrogate for blood-brain barrier permeability in ischemia-affected brain regions and matrix metalloproteinase (MMP)-2 (A) as well as MMP-9 (B) serum levels depending on treatment**. Underlying degrees of freedom *(df)*: In both (A) and (B) for controls n = 13, for NBO n = 13, for HBO n = 12, for tPA n = 11, and for tPA+HBO n = 13. Coefficient significance level: \*: *P*\< 0.05.](2045-9912-2-2-1){#F1}

###### 

Time point-corrected partial correlation coefficients between BBB-related serum markers in control animals.

  -----------------------------------------------------------
               MMP-2   MMP-9        TIMP-1       TIMP-2
  ------------ ------- ------------ ------------ ------------
  **MMP-2**    \-      0.199\       0.083\       0.345\
                       *P*= 0.478   *P*= 0.768   *P*= 0.207

  **MMP-9**            \-           -0.055\      -0.314\
                                    *P*= 0.844   *P*= 0.254

  **TIMP-1**                        \-           0.302\
                                                 *P*= 0.274

  **TIMP-2**                                     \-
  -----------------------------------------------------------

Underlying degrees of freedom *(df)*: n = 13.

###### 

Time point-corrected partial correlation coefficients between BBB-related serum markers in animals treated with NBO (upper right) or HBO (lower left).

  ------------------------------------------------------------------------
               MMP-2        MMP-9            TIMP-1           TIMP-2
  ------------ ------------ ---------------- ---------------- ------------
  **MMP-2**    \-           0.240\           0.217\           0.071\
                            *P*= 0.389       *P*= 0.437       *P*= 0.801

  **MMP-9**    0.130\       \-               -0.161\          0.341\
               *P*= 0.657                    *P*= 0.567       *P*= 0.214

  **TIMP-1**   0.012\       **0.710**\       \-               0.024\
               *P*= 0.967   ***P*= 0.004**                    *P*= 0.932

  **TIMP-2**   0.085\       **0.626**\       **0.764**\       \-
               *P*= 0.773   ***P*= 0.017**   ***P*= 0.001**   
  ------------------------------------------------------------------------

Underlying degrees of freedom *(df)*: for NBO n = 13, for HBO n = 12.

###### 

Time point-corrected partial correlation coefficients between BBB-related serum markers in animals treated with tPA alone (upper right) or tPA+HBO (lower left).

  ----------------------------------------------------------------------------
               MMP-2            MMP-9        TIMP-1           TIMP-2
  ------------ ---------------- ------------ ---------------- ----------------
  **MMP-2**    \-               0.277\       0.325\           0.445\
                                *P*= 0.360   *P*= 0.279       *P*= 0.128

  **MMP-9**    -0.045\          \-           0.425\           **0.725**\
               *P*= 0.873                    *P*= 0.148       ***P*= 0.005**

  **TIMP-1**   **0.628**\       0.155\       \-               **0.757**\
               ***P*= 0.012**   *P*= 0.580                    ***P*= 0.003**

  **TIMP-2**   **0.834**\       0.306\       **0.760**\       \-
               ***P*= 0.000**   *P*= 0.268   ***P*= 0.001**   
  ----------------------------------------------------------------------------

Underlying degrees of freedom *(df)*: for tPA n = 11, for tPA+HBO n = 13.

Despite its retrospective design, the present study provided clinically relevant insights in interactions of stroke-related BBB permeability with associated MMPs and TIMPs in consideration of tPA as approved treatment for ischemic stroke \[[@B1]\], and hyperoxia as potential neuroprotective co-treatment \[[@B16]\]. Thereby, HBO was chosen since a previous report has already tested the combination of NBO and tPA \[[@B23]\]. Concerning translational aspects, efforts were made to use an embolic model for focal cerebral ischemia, representing probably the best comparability to the human pathophysiology \[[@B24]\]. Furthermore, BBB-related changes based on the leakage marker FITC-albumin and BBB-associated serum markers were assessed simultaneously, which required specific brain tissue preparations for immunofluorecence labeling \[[@B22]\] and significant correlations between plasma and brain levels of MMPs, as shown by a previous study for MMP-9 \[[@B25]\].

The first main finding of the present study was the ability of hyperoxia to reverse the (in controls positively directed) association of BBB permeability, MMP-2 and -9 when administered 2 hours after ischemia onset. This effect was most pronounced for MMP-9 and treatment with HBO, suggesting a specific influence of HBO on BBB regulation. Based on the presented data the previously reported tendency for BBB stabilization following HBO administration 2 hours after eMCAO \[[@B20]\] might be attributed to an interruption of the MMP-9-related increase of BBB permeability. This view is supported by former studies showing an attenuated MMP-9 upregulation after experimental stroke treated with hyperoxia \[[@B17],[@B19]\]. As already known from earlier reports, treatment with tPA leads to an increase in BBB permeability that is mainly caused by MMP-9 activation \[[@B2],[@B10],[@B12]\], which was confirmed by our data (positive correlation coefficient between BBB permeability and MMP-9). Concerning the potential neuroprotective effect of HBO when simultaneously applied to tPA and its clinical potential, we found that this approach attenuated, and actually reversed the effect of tPA in part, but this effect was less pronounced than after treatment with HBO alone. However, these data suggest that HBO simultaneously applied to tPA starting 2 hours after experimental stroke does not result in the assumed neuroprotective effect *via*a significant prevention of the MMP-9-related increase in BBB permeability. Moreover, this finding should be seen in context with our previous study \[[@B20]\] which noted a tendency towards increased BBB permeability and plasma concentrations of MMPs and TIMPs when addressed separately and, therefore, opens up a critical perspective on this combined approach.

The second part of the present study addressed interrelations of MMPs and TIMPs. Here, we found mainly week and non-significant associations in controls and NBO-treated animals. This situation clearly changed after treatment with HBO, tPA and the combined approach: HBO and tPA led to significant positive associations between MMP-9 and TIMP-2, and in part MMP-9 and TIMP-1. However, treatment with tPA+HBO resulted in a shift towards significant positive associations between MMP-2 and TIMP-1/-2, while MMP-9 provided non-significant coefficients. Interestingly, a significant correlation coefficient between TIMP-1 and -2 was found for all types of treatment with the exception of NBO. Why this association was also present for HBO without concomitant tPA treatment remains open and requires further evaluation. Unfortunately, a clear interpretation of these mediator-related changes is still impeded by the complexity of MMP activation, including the expression of pro-MMPs, the interference with other MMPs (e.g., MMP-3) \[[@B4]\], and non-selective inhibitory processes by TIMPs \[[@B8]\] with reported positive and negative effects depending on the time course of ischemia \[[@B3]\].
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